



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/587,476	07/26/2006	Elvir Causevic	KEDI 8309 W1	5338
1688 7590 10/17/2007 POLSTER, LIEDER, WOODRUFF & LUCCHESI 12412 POWERSCOURT DRIVE SUITE 200 ST. LOUIS, MO 63131-3615			EXAMINER SZMAL, BRIAN SCOTT	
			ART UNIT 3736	PAPER NUMBER
			MAIL DATE 10/17/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

## Office Action Summary

Application No.

10/587,476

Applicant(s)

CAUSEVIC, ELVIR

Examiner

Brian Szmal

Art Unit

3736

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-22, 24 and 25 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-22, 24 and 25 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date 7/26/06
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_

***Claim Objections***

1. Claims 6, 8, 11 and 12 are objected to because of the following informalities: all of the claims disclose "a patient" should read as "the patient". Appropriate correction is required.
2. Claim 16 is objected to because of the following informalities: In line 8, "points" should read as "point". Appropriate correction is required.

***Claim Rejections - 35 USC § 102***

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

4. Claims 1, 2, 9-15, 19-22, 24 and 25 are rejected under 35 U.S.C. 102(e) as being anticipated by Causevic et al (6,866,639 B2).

Causevic et al disclose a handheld testing means and further disclose a plurality of independently operable modular testing subsystems, the subsystems comprising at least: an auditory response testing subsystem, configured to measure a response of the patient to an auditory stimulus, the response being representative of a first indicator; at least one non-auditory response testing subsystem configured to measure at least one characteristic of the patient, the characteristic being representative of at least one

Art Unit: 3736

additional indicator of the at least one disorder; a processor system coupled to each of the modules, the processor system being configured with a computer program to selectively operate each of the module testing subsystems and to generate an index value representative of the at least one disorder responsive to a plurality of indicators of the at least one disorder generated by at least two of the modular testing subsystems; a breath gas monitoring subsystem; at least a first connection point on the enclosure for coupling at least a first instrument to the auditory response testing subsystem; at least a second connection point on the enclosure for coupling at least a second instrument to the at least one non-auditory response testing subsystem; a power supply; the first and second instruments are selected from microphones, acoustic emitters, electrodes, gas analyzers and optical sensors; the at least one non-auditory response subsystem includes a bioelectric signal measurement subsystem, the bioelectric signal measurement subsystem being configured to measure at least one bioelectric signal from the patient; the processor is configured to evaluate the bioelectric signal to detect at least one anomaly representative of a medical disorder in the patient; the bioelectric signals include EEG signals or ECG signals; the processor is configured to selectively display test results from a single testing subsystem; and the processor is configured to selectively display a cumulative index generated from measurements acquired by a plurality of testing subsystems, the cumulative index being representative of a medical condition of the patient. See Figures 1-3; Column 4, lines 56-67; Column 5, lines 1-40; Column 7, lines 17-36; Column 8, lines 63-67; Column 9, lines 1-37; and Column 13, lines 8-14.

Art Unit: 3736

5. Claims 1, 5, 9-15, 24 and 25 are rejected under 35 U.S.C. 102(e) as being anticipated by Meyerson et al (6,589,189 B2).

Meyerson et al disclose a noninvasive means for monitoring a patient and further disclose a plurality of independently operable modular testing subsystems, the subsystems comprising at least: an auditory response testing subsystem, configured to measure a response of the patient to an auditory stimulus, the response being representative of a first indicator; at least one non-auditory response testing subsystem configured to measure at least one characteristic of the patient, the characteristic being representative of at least one additional indicator of the at least one disorder; a processor system coupled to each of the modules, the processor system being configured with a computer program to selectively operate each of the module testing subsystems and to generate an index value representative of the at least one disorder responsive to a plurality of indicators of the at least one disorder generated by at least two of the modular testing subsystems; a blood analysis subsystem; at least a first connection point on the enclosure for coupling at least a first instrument to the auditory response testing subsystem; at least a second connection point on the enclosure for coupling at least a second instrument to the at least one non-auditory response testing subsystem; a power supply; the first and second instruments are selected from microphones, acoustic emitters, electrodes, gas analyzers and optical sensors; the at least one non-auditory response subsystem includes a bioelectric signal measurement subsystem, the bioelectric signal measurement subsystem being configured to measure at least one bioelectric signal from the patient; the processor is configured to evaluate

Art Unit: 3736

the bioelectric signal to detect at least one anomaly representative of a medical disorder in the patient; the bioelectric signals include EEG signals or ECG signals; the processor is configured to selectively display test results from a single testing subsystem; and the processor is configured to selectively display a cumulative index generated from measurements acquired by a plurality of testing subsystems, the cumulative index being representative of a medical condition of the patient. See Figures 3, 4 and 8; Column 8, lines 62-67; Column 9, lines 1-4 and 15-16; Column 10, lines 50-67; Column 11, lines 1-3 and 58-64.

***Claim Rejections - 35 USC § 103***

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. Claims 3 and 4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Causevic et al (6,866,639 B2) as applied to claim 1 above, and further in view of Smits et al (6,544,190 B1).

Causevic et al, as discussed above, disclose a means for obtaining multiple measurements from a patient, but fail to disclose the breath gas monitoring subsystem is configured to measure at least a concentration of carbon monoxide from the patient, the carbon monoxide concentration being an indicator of a hemolysis condition; the

Art Unit: 3736

breath gas monitoring subsystem is configured to measure a concentration of breath gas from the set of oxygen, carbon dioxide, nitrous oxide and nitrous dioxide.

Smits et al disclose a means for analyzing breath samples and further disclose the breath gas monitoring subsystem is configured to measure at least a concentration of carbon monoxide from the patient, the carbon monoxide concentration being an indicator of a hemolysis condition; the breath gas monitoring subsystem is configured to measure a concentration of breath gas from the set of oxygen, carbon dioxide, nitrous oxide and nitrous dioxide. See Column 3, lines 16-19.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the means of Causevic et al to include the ability to analyze breath samples, as per the teachings of Smits et al, since it would provide a means of monitoring other parameters of the patient.

8. Claims 2-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Meyerson et al (6,589,189 B2) as applied to claim 1 above, and further in view of Smits et al (6,544,190 B1).

Meyerson et al, as discussed above, disclose a means for obtaining measurements from a patient but fail to disclose the at least one non-auditory response testing subsystem includes a breath gas monitoring subsystem; the breath gas monitoring subsystem is configured to measure at least a concentration of carbon monoxide from the patient, the carbon monoxide concentration being an indicator of a hemolysis condition; the breath gas monitoring subsystem is configured to measure a

Art Unit: 3736

concentration of breath gas from the set of oxygen, carbon dioxide, nitrous oxide and nitrous dioxide.

Smits et al, as discussed above, disclose a means for analyzing breath gas, and further disclose the at least one non-auditory response testing subsystem includes a breath gas monitoring subsystem; the breath gas monitoring subsystem is configured to measure at least a concentration of carbon monoxide from the patient, the carbon monoxide concentration being an indicator of a hemolysis condition; the breath gas monitoring subsystem is configured to measure a concentration of breath gas from the set of oxygen, carbon dioxide, nitrous oxide and nitrous dioxide. See Column 3, lines 16-19.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the means of Meyerson et al to include the use of a breath gas analyzer, as per the teachings of Smits et al, since it would provide an additional means of analyzing the condition of the patient.

9. Claims 5-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Causevic et al (6,866,639 B2) as applied to claim 1 above, and further in view of Mault et al (2003/0208113 A1).

Causevic et al, as discussed above, disclose a means for obtaining multiple measurements from a patient, but fail to disclose a blood analysis subsystem; the blood analysis subsystem is configured to measure the presence or absence of at least one chemical compound indicative of a hemolysis condition of the patient; and the blood analysis subsystem is further configured for noninvasive optical blood analysis.



Mault et al discloses a blood analyte monitoring system and further disclose a blood analysis subsystem; the blood analysis subsystem is configured to measure the presence or absence of at least one chemical compound indicative of a hemolysis condition of the patient; and the blood analysis subsystem is further configured for noninvasive optical blood analysis. See Paragraphs 0201, 0203 and 0204. Lactate concentration in the blood is an indicator of hemolysis.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the means of Causevic et al to include the use of a blood analyte monitoring means, as per the teachings of Mault et al, since it would provide an additional means of monitoring parameters of a patient to determine a medical condition.

10. Claims 6 and 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Meyerson et al (6,589,189 B2) as applied to claim 1 above, and further in view of Mault et al (2003/0208113 A1).

Meyerson et al, as discussed above, disclose a means for measuring parameters of a patient, but fail to disclose the blood analysis subsystem is configured to measure the presence or absence of at least one chemical compound indicative of a hemolysis condition of the patient; and the blood analysis subsystem is further configured for noninvasive optical blood analysis.

Mault et al discloses a blood analyte monitoring system and further disclose the blood analysis subsystem is configured to measure the presence or absence of at least one chemical compound indicative of a hemolysis condition of the patient; and the blood

Art Unit: 3736

analysis subsystem is further configured for noninvasive optical blood analysis. See Paragraphs 0201, 0203 and 0204. Lactate concentration in the blood is an indicator of hemolysis.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the means of Meyerson et al to include the use of a blood analyte monitoring means, as per the teachings of Mault et al, since it would provide an additional means of monitoring parameters of a patient to determine a medical condition.

11. Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over Causevic et al (6,866,639 B2) and Mault et al (2003/0208113 A1) as applied to claim 7 above, and further in view of Jay et al (2004/0138539 A1).

Causevic et al and Mault et al, as discussed above, disclose a means for monitoring at least one medical condition of a patient but fail to disclose the blood analysis subsystem is configured to measure at least a presence or absence of at least one chemical compound indicative of a lactose malabsorption condition of the patient.

Jay et al disclose blood monitor and further disclose the blood analysis subsystem is configured to measure at least a presence or absence of at least one chemical compound indicative of a lactose malabsorption condition of the patient. See Paragraph 0064. The measurement of lactose in the bloodstream would provide an indicator of the absorption of lactose by the body.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the combination of Causevic et al and Mault et al to

Art Unit: 3736

include the ability to measure the lactose concentration in the blood, as per the teachings of Jay et al, since it would provide a means of monitoring an additional parameter of the patient.

12. Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over Meyerson et al (6,589,189 B2) and Mault et al (2003/0208113 A1) as applied to claim 7 above, and further in view of Jay et al (2004/0138539 A1).

Meyerson et al and Mault et al, as discussed above, disclose a means for monitoring blood parameters to determine a medical condition but fail to disclose the blood analysis subsystem is configured to measure at least a presence or absence of at least one chemical compound indicative of a lactose malabsorption condition of the patient.

Jay et al disclose blood monitor and further disclose the blood analysis subsystem is configured to measure at least a presence or absence of at least one chemical compound indicative of a lactose malabsorption condition of the patient. See Paragraph 0064. The measurement of lactose in the bloodstream would provide an indicator of the absorption of lactose by the body.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the combination of Meyerson et al and Mault et al to include the ability to measure the lactose concentration in the blood, as per the teachings of Jay et al, since it would provide a means of monitoring an additional parameter of the patient.

Art Unit: 3736

13. Claims 16-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Causevic et al (6,866,639 B2) in view of Mault et al (2003/0208113 A1).

Causevic et al, as discussed above, disclose a means of monitoring a medical condition of a patient and further disclose a portable handheld enclosure; a plurality of testing subsystems; at least one connection point on the enclosure for coupling at least one instrument to the testing subsystem; a power supply; an auditory screening subsystem, a breath analyzer, and a bioelectric signal measurement subsystem; at least one of the instruments is selected from the group of microphones, acoustic emitters, electrodes, gas collectors and optical sensors; a processor in the enclosure; a display; and a computer program. See Figures 1-3; Column 4, lines 56-67; Column 5, lines 1-40; Column 7, lines 17-36; Column 8, lines 63-67; Column 9, lines 1-37; and Column 13, lines 8-14.

Causevic et al however fail to disclose monitoring a medical condition including hemolysis; and the blood analysis subsystem is a noninvasive optical blood analysis subsystem.

Mault et al, as discussed above, disclose a blood analysis means and further disclose monitoring a medical condition including hemolysis; and the blood analysis subsystem is a noninvasive optical blood analysis subsystem. See Paragraphs 0201, 0203 and 0204. Lactate concentration in the blood is an indicator of hemolysis.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the means of Causevic et al to include the use of a blood analyte monitoring means, as per the teachings of Mault et al, since it would provide an

Art Unit: 3736

additional means of monitoring parameters of a patient to determine a medical condition.

14. Claims 16-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Meyerson et al (6,589,189 B2) in view of Mault et al (2003/0208113 A1).

Meyerson et al, as discussed above, disclose a means for monitoring the condition of a patient, and further disclose a portable handheld enclosure; a plurality of testing subsystems; at least one connection point on the enclosure for coupling at least one instrument to the testing subsystem; a power supply; an auditory screening subsystem, a breath analyzer, and a bioelectric signal measurement subsystem; a blood analysis subsystem; at least one of the instruments is selected from the group of microphones, acoustic emitters, electrodes, gas collectors and optical sensors; a processor in the enclosure; a display; and a computer program. See Figures 3, 4 and 8; Column 8, lines 62-67; Column 9, lines 1-4 and 15-16; Column 10, lines 50-67; Column 11, lines 1-3 and 58-64.

Meyerson et al however fail to disclose monitoring the patient for the medical condition of hemolysis.

Mault et al, as discussed above, disclose a blood analysis means and further disclose monitoring a medical condition including hemolysis. See Paragraphs 0201, 0203 and 0204. Lactate concentration in the blood is an indicator of hemolysis.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the means of Meyerson et al to include the use of a blood analyte monitoring means, as per the teachings of Mault et al, since it would provide an

Art Unit: 3736

additional means of monitoring parameters of a patient to determine a medical condition:

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Szmaj whose telephone number is (571) 272-4733. The examiner can normally be reached on Monday-Friday, with second Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Max Hindenburg can be reached on (571) 272-4726. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Brian Szmaj